<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li J</submitter><funding>National Natural Science Foundation of China</funding><funding>China Postdoctoral Science Foundation</funding><funding>National Key Research and Development Program of China</funding><pagination>2135-2152</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9168967</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(11)</volume><pubmed_abstract>Primary liver cancer, mainly comprising hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), remains a major global health problem. Although ICC is clinically different from HCC, their molecular differences are still largely unclear. In this study, precision N-glycoproteomic analysis was performed on both ICC and HCC tumors as well as paracancer tissues to investigate their aberrant site-specific N-glycosylation. By using our newly developed glycoproteomic methods and novel algorithm, termed 'StrucGP', a total of 486 N-glycan structures attached on 1235 glycosites were identified from 894 glycoproteins in ICC and HCC tumors. Notably, glycans with uncommon LacdiNAc (GalNAcβ1-4GlcNAc) structures were distinguished from their isomeric glycans. In addition to several bi-an</pubmed_abstract><journal>Molecular oncology</journal><pubmed_title>Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma.</pubmed_title><pmcid>PMC9168967</pmcid><funding_grant_id>91853123</funding_grant_id><funding_grant_id>81773180</funding_grant_id><funding_grant_id>2019TQ0260</funding_grant_id><funding_grant_id>2019M663798</funding_grant_id><funding_grant_id>21705127</funding_grant_id><funding_grant_id>81800655</funding_grant_id><funding_grant_id>32101192</funding_grant_id><funding_grant_id>2019YFA09005200</funding_grant_id><pubmed_authors>Dang L</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Shen J</pubmed_authors><pubmed_authors>Ma C</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Mu F</pubmed_authors><pubmed_authors>Zhao T</pubmed_authors><pubmed_authors>Hu L</pubmed_authors><pubmed_authors>Zhu B</pubmed_authors><pubmed_authors>Liu D</pubmed_authors><pubmed_authors>Jia L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma.</name><description>Primary liver cancer, mainly comprising hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), remains a major global health problem. Although ICC is clinically different from HCC, their molecular differences are still largely unclear. In this study, precision N-glycoproteomic analysis was performed on both ICC and HCC tumors as well as paracancer tissues to investigate their aberrant site-specific N-glycosylation. By using our newly developed glycoproteomic methods and novel algorithm, termed 'StrucGP', a total of 486 N-glycan structures attached on 1235 glycosites were identified from 894 glycoproteins in ICC and HCC tumors. Notably, glycans with uncommon LacdiNAc (GalNAcβ1-4GlcNAc) structures were distinguished from their isomeric glycans. In addition to several bi-an</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-03T22:37:29.212Z</modification><creation>2025-04-03T22:37:29.212Z</creation></dates><accession>S-EPMC9168967</accession><cross_references><pubmed>34855283</pubmed><doi>10.1002/1878-0261.13147</doi></cross_references></HashMap>